RxDoctor Payments Data

Billy Nordyke, DO

Family Medicine · Wyandotte, MINPI 1700817558

Payments from drug & device makers

$5,968in general payments, 2019–2025

Across 308 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$556
  • AstraZeneca$554
  • GSK$521
  • Amgen$442
  • Otsuka America Pharmaceutical, Inc.$436
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,947100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,968 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,513
Medicare patients
81
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$61,198
EliquisApixaban21$18,760
JardianceEmpagliflozin18$16,772
LinzessLinaclotide23$16,129
TrulicityDulaglutide17$16,116
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,938
FarxigaDapagliflozin Propanediol12$11,015
Albuterol Sulfate HfaAlbuterol Sulfate288$7,482
TrintellixVortioxetine Hydrobromide15$6,873
Spiriva HandihalerTiotropium Bromide11$6,310
SymbicortBudesonide/Formoterol Fumarate26$5,852
Breo ElliptaFluticasone/Vilanterol14$5,334
Incruse ElliptaUmeclidinium Bromide13$4,307
Admelog SolostarInsulin Lispro23$4,198
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$521$70,839108 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$554$32,80557 claims
PfizerEliquis$350$18,76021 claims
AbbVieLinzess$1,035$16,12923 claims
Lilly USA, LLCTrulicity$32$16,11617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Wyandotte

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →